Breast cancer studies funded by drug companies are more likely to yield positive findings than those without pharmaceutical industry backing, according to research published on Monday.
A team led by Dr. Jeffrey Peppercorn of the University of North Carolina School of medicine also found industry-backed studies tended to be designed differently than the others, but he said drug companies may simply be backing the least-risky alternatives.
Wow! In other news, Joe Lieberman's reports more likely to show Iraq a success than those without psychotic delusions.
No comments:
Post a Comment